Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance

International Journal of Molecular Sciences
Alvaro Garcia-RoperoJuan J Badimon

Abstract

The sodium-glucose cotransporter (SGLT) inhibitors represent a new alternative for treating patients with diabetes mellitus. They act primarily by inhibiting glucose reabsorption in the renal tubule and therefore, decreasing blood glucose levels. While little is yet known about SGLT subtype 1, SGLT2 inhibitors have demonstrated to significantly reduce cardiovascular mortality and heart failure hospitalizations. This cardioprotective benefit seems to be independent of their glucose-lowering properties; however, the underlying mechanism(s) remains still unclear and numerous hypotheses have been postulated to date. Moreover, preclinical research has suggested an important role of SGLT1 receptors on myocardial ischemia. Following acute phase of cardiac injury there is an increased activity of SGLT1 cotransport that ensures adequate energy supply to the cardiac cells. Nonetheless, a long-term upregulation of this receptor may not be that beneficial and whether its inhibition is positive or not should be further addressed. This review aims to present the most cutting-edge insights into SGLT receptors.

References

Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·Y T ZhouR H Unger
Jul 11, 2000·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·L H YoungR R Russell
Jan 22, 2004·Biochemical and Biophysical Research Communications·Katrin ElfeberHermann Koepsell
Nov 9, 2005·Circulation·Ferhaan AhmadJ G Seidman
May 13, 2006·The Journal of Physiology·Jason R B Dyck, Gary D Lopaschuk
Jun 11, 2009·Cardiovascular Research·Sanjay K BanerjeeFerhaan Ahmad
Jul 6, 2010·Journal of Molecular and Cellular Cardiology·Sanjay K BanerjeeFerhaan Ahmad
Jan 12, 2011·Journal of Molecular and Cellular Cardiology·Gemma VilahurLina Badimon
Mar 4, 2011·The New England Journal of Medicine·Hertzel C GersteinWilliam T Friedewald
Aug 13, 2013·International Journal of Cardiology·Xavier PalomerManuel Vázquez-Carrera
Aug 31, 2013·Circulation Research·Torsten DoenstE Dale Abel
Oct 2, 2013·Journal of Molecular and Cellular Cardiology·Vikram PrasadGary E Shull
Jul 1, 2015·Current Opinion in Nephrology and Hypertension·Søren Brandt PoulsenTimo Rieg
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Mar 22, 2016·Expert Opinion on Therapeutic Targets·Panai SongVolker Vallon
Jun 12, 2016·Diabetes Care·Ele FerranniniEric Mayoux
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Dec 31, 2016·International Journal of Cardiology·Leszek Szablewski
May 21, 2017·International Journal of Cardiology·Alessandra Di FrancoEdoardo Mannucci
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Aug 20, 2017·Pharmacology & Therapeutics·Hannah NoordaliMelanie Madhani
Sep 26, 2017·JACC. Basic to Translational Science·Adam R WendeMartin E Young
Apr 22, 2018·Cardiovascular Drugs and Therapy·Eduardo FloresJuan Jose Badimon
Jun 20, 2018·Diabetes Technology & Therapeutics·Thomas DanneOlga Kordonouri
Jun 26, 2018·The Lancet. Diabetes & Endocrinology·Vlado PerkovicBruce Neal
Jul 20, 2018·ESC Heart Failure·Stefan D Anker, Javed Butler
Nov 13, 2018·The New England Journal of Medicine·Stephen D WiviottUNKNOWN DECLARE–TIMI 58 Investigators
Nov 23, 2018·Expert Opinion on Drug Metabolism & Toxicology·Alvaro Garcia-RoperoCarlos G Santos-Gallego
Jan 8, 2019·Circulation·Stephen J Greene, Javed Butler

❮ Previous
Next ❯

Citations

Nov 6, 2020·International Journal of Nephrology and Renovascular Disease·George Vasquez-Rios, Girish N Nadkarni
Jun 18, 2021·The Nurse Practitioner·Christy McDonald LenahanFrances Stueben

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03485222
NCT03057977
NCT03057951

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.